Agile Therapeutics, Inc. (NASDAQ:AGRX) – Research analysts at William Blair boosted their FY2017 earnings estimates for Agile Therapeutics in a research report issued on Tuesday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings per share of ($0.96) for the year, up from their previous estimate of ($1.03). William Blair also issued estimates for Agile Therapeutics’ Q4 2017 earnings at ($0.22) EPS and FY2018 earnings at ($0.56) EPS.
A number of other equities analysts also recently issued reports on the company. Royal Bank Of Canada set a $8.00 price target on Agile Therapeutics and gave the stock a “buy” rating in a research note on Sunday, July 16th. HC Wainwright began coverage on Agile Therapeutics in a research note on Wednesday, July 19th. They issued a “buy” rating and a $10.00 price target on the stock. Janney Montgomery Scott restated a “buy” rating and issued a $15.00 price target on shares of Agile Therapeutics in a research note on Friday, July 21st. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.20.
Shares of Agile Therapeutics (NASDAQ:AGRX) opened at $4.59 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 3.37. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $7.39.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.03.
In other news, Chairman Alfred Altomari purchased 10,000 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the purchase, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.50% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $122,000. Franklin Resources Inc. lifted its position in Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after purchasing an additional 780,578 shares in the last quarter. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the second quarter valued at $205,000. Royce & Associates LP lifted its position in Agile Therapeutics by 1.1% during the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 11,000 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Agile Therapeutics during the third quarter valued at $467,000. Hedge funds and other institutional investors own 67.52% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.